
    
      This study was designed as a multi-center, randomized, double-blind, placebo-controlled,
      parallel-group, phase 3 study to assess the efficacy and safety of oral administration of
      DWP14012 X mg QD, Y mg BID and placebo for 2 weeks in patients with acute and chronic
      gastritis.
    
  